In preclinical models, CAR-associated CRS is linked with myeloid cell release of IL-1 and IL-6, corroborating the current clinical method of CRS control with the use of the anti-IL-6 antibody tocilizumab and offering an option for IL-1 antagonists in the control of CRS (17, 18). Here, IL6 is linked to congenital rubella syndrome.